Project Grant R44CA298064
Award Date
6/1/25
Completion Date
5/31/28
Dollars Obligated
$658K
Federal Agency
National Cancer Institute
Awardee
Rarecyte, Inc. (N6CVCHBTWT86)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This $554,653 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of "RARECYTEFINDER", a label-free, genome-wide copy number-based method for the unbiased identification and comprehensive molecular analysis of rare disseminated tumor cells (DTCs) in liquid and tissue biopsies. The key objectives of this 4-year project are to: 1) advance and validate the RARECYTEFINDER...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to O2M Technologies LLC, a small for-profit corporation, to develop a Multifunctional Imager (MFI) capable of simultaneously generating 3D maps of tissue oxygen pressure (pO2) and pH. The goal of this 1-year project is to create an advanced electron paramagnetic resonance imaging (EPRI) instrument that can perform both pulse and continuous wave...
The National Cancer Institute (NCI) awarded Carnegie Mellon University a $632,300 Project Grant under the Cancer Biology Research program (CFDA 93.396) to develop an integrated ultra-high-throughput 3D volumetric super-resolution imaging system. This system combines a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional subcellular detail. The goal is to study the interactions between cancer and immune cells in situ,...
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $440,287 project grant to GE Medical Systems Information Technologies, Inc. (doing business as GE Healthcare Technology & Innovation Center) to establish a simplified and accessible procedure for simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This approach aims to democratize cancer biobanking by enabling lower-resource institutes to conduct...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Broad Institute, Inc. to develop a spatial genomics platform for profiling human tumors. The project aims to enhance the Broad Institute's recently invented "Slide-Tags" technology to enable comprehensive, multi-modal spatial analysis of tumor samples, including measuring transcription, epigenetics, and genome variation within individual cells in the tumor...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant supports the development of a novel nanopore-based sequencing approach to accurately characterize repetitive DNA sequences, which are critical for understanding cancer progression but challenging to analyze using current sequencing-by-synthesis methods. The...
This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $593,383 to The Methodist Hospital Research Institute (HMRI) for the development of an AI-augmented, multimodal, label-free nonlinear optical microscopy system. This innovative system aims to enable rapid and precise diagnosis of thyroid cancer and lymph node metastasis, eliminating the need for external dyes and addressing the drawbacks...
The National Cancer Institute (NCI) awarded a $549,536 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Trustees of Dartmouth College. The purpose of this 5-year project is to develop a 3D wearable near-infrared (NIR) spectral tomography system to enable early prediction of residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy. The proposed innovations focus on transitioning the NIR spectral tomography technology from...
This $990,771 Project Grant awarded by the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to build clinical utility data for a novel circulating tumor DNA (ctDNA) assay technology developed by Binary Genomics, Inc. to monitor immunotherapy response in lung cancer patients. The technology leverages epigenetic features found across cancer genomes, allowing broad patient coverage without requiring tumor profiling or assay...